lentiviral vlp stock  (Worthington Biochemical)


Bioz Verified Symbol Worthington Biochemical is a verified supplier
Bioz Manufacturer Symbol Worthington Biochemical manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Name:
    Deoxyribonuclease I
    Description:
    Chromatographically purified A lyophilized powder with glycine as a stabilizer
    Catalog Number:
    ls002004
    Price:
    33
    Size:
    5 mg
    Source:
    Bovine Pancreas
    Cas Number:
    9003.98.9
    Buy from Supplier


    Structured Review

    Worthington Biochemical lentiviral vlp stock
    Nullbasic does not inhibit the production of <t>lentiviral</t> VLPs. (a) Schematic diagrams of the three <t>VLP</t> expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Chromatographically purified A lyophilized powder with glycine as a stabilizer
    https://www.bioz.com/result/lentiviral vlp stock/product/Worthington Biochemical
    Average 85 stars, based on 1155 article reviews
    Price from $9.99 to $1999.99
    lentiviral vlp stock - by Bioz Stars, 2021-01
    85/100 stars

    Images

    1) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Figure Legend Snippet: Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Techniques Used: Expressing, Plasmid Preparation

    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Figure Legend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Techniques Used: Purification, Activity Assay

    2) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced
    Figure Legend Snippet: Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Techniques Used: Infection, Produced

    HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was
    Figure Legend Snippet: HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Techniques Used: Expressing, Infection

    HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were
    Figure Legend Snippet: HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Techniques Used: Expressing, Infection

    3) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic inhibits reverse transcription of lentiviral VLPs.  (a)  Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Figure Legend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Techniques Used: Purification, Activity Assay

    Related Articles

    In Vivo:

    Article Title: Nucleosomes Are Translationally Positioned on the Active Allele and Rotationally Positioned on the Inactive Allele of the HPRT Promoter
    Article Snippet: .. In vivo DNase I footprint analysis was performed by treating permeabilized 4.12 and 8121 cells with increasing concentrations of DNase I, purifying the DNase I-treated genomic DNA, and examining the DNase I cleavage pattern in the region of interest by LMPCR. ..

    Concentration Assay:

    Article Title: A Cellular Protein Binds Vaccinia Virus Late Promoters and Activates Transcription In Vitro
    Article Snippet: .. DNase I (Worthington Biochemicals) was added to a concentration of 8 ng/ml, and incubation was continued for an additional 2 min, after which the cleavage reaction was terminated by addition of an equal volume of a stop solution (0.2 M NaCl, 30 mM EDTA, 1% sodium dodecyl sulfate, and 100 μg of glycogen/ml). .. DNA cleavage products were extracted with phenol-chloroform, precipitated with ethanol, and analyzed on a 6% polyacrylamide DNA sequencing gel.

    Incubation:

    Article Title: A Cellular Protein Binds Vaccinia Virus Late Promoters and Activates Transcription In Vitro
    Article Snippet: .. DNase I (Worthington Biochemicals) was added to a concentration of 8 ng/ml, and incubation was continued for an additional 2 min, after which the cleavage reaction was terminated by addition of an equal volume of a stop solution (0.2 M NaCl, 30 mM EDTA, 1% sodium dodecyl sulfate, and 100 μg of glycogen/ml). .. DNA cleavage products were extracted with phenol-chloroform, precipitated with ethanol, and analyzed on a 6% polyacrylamide DNA sequencing gel.

    other:

    Article Title: Structural and functional conservation at the boundaries of the chicken ?-globin domain
    Article Snippet: The DNase I HS, 3′HS, was detected by digestion of nuclei with increasing amounts of DNase I as above followed by digestion of extracted DNA with Kpn I and probing with i112 (1000 bp; Kpn I –Pst I at 23.3–24.3 map units).

    Article Title: Structural and functional conservation at the boundaries of the chicken ?-globin domain
    Article Snippet: [ ] [ ] Stalder J., Larsen,A., Engel,J.D., Dolan,M., Groudine,M. and Weintraub,H. (1980) Tissue-specific DNA cleavages in the globin chromatin domain introduced by DNase I.

    Activity Assay:

    Article Title: Dynamic BRG1 Recruitment during T Helper Differentiation and Activation Reveals Distal Regulatory Elements ▿Dynamic BRG1 Recruitment during T Helper Differentiation and Activation Reveals Distal Regulatory Elements ▿ §
    Article Snippet: .. Newly identified distal BRG1 binding regions in the GATA3 locus were specific with respect to fate and hypersensitive to DNase I and possessed BRG1-dependent enhancer-like activity. .. BRG1 binding to these regions was dependent on the presence of STAT6.

    Sequencing:

    Article Title: Role of the Promoter in Maintaining Transcriptionally Active Chromatin Structure and DNA Methylation Patterns In Vivo
    Article Snippet: .. It is possible that the steeper slope detected by this probe is indicative of an intrinsically higher accessibility of the 5′flanking region to DNase I (or preferential DNase I cleavage of the underlying DNA sequence). ..

    Staining:

    Article Title: Constitutive Nucleosome Depletion and Ordered Factor Assembly at the GRP78 Promoter Revealed by Single Molecule Footprinting
    Article Snippet: .. These were then digested at 37 °C for 15 min using various concentrations of DNase I (Worthington, San Francisco, California, United States) to obtain a suitable range of digestion of genomic DNA as revealed by EtBr staining. .. Digested genomic DNA was purified, redigested by RsaI, resolved on a 1.5% agarose gel, and Southern blotted.

    Binding Assay:

    Article Title: Dynamic BRG1 Recruitment during T Helper Differentiation and Activation Reveals Distal Regulatory Elements ▿Dynamic BRG1 Recruitment during T Helper Differentiation and Activation Reveals Distal Regulatory Elements ▿ §
    Article Snippet: .. Newly identified distal BRG1 binding regions in the GATA3 locus were specific with respect to fate and hypersensitive to DNase I and possessed BRG1-dependent enhancer-like activity. .. BRG1 binding to these regions was dependent on the presence of STAT6.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Worthington Biochemical dnase i
    Nullbasic inhibits reverse transcription of lentiviral VLPs.  (a)  Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Dnase I, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 99/100, based on 431 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dnase i/product/Worthington Biochemical
    Average 99 stars, based on 431 article reviews
    Price from $9.99 to $1999.99
    dnase i - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    85
    Worthington Biochemical lentiviral vlp stock
    Nullbasic does not inhibit the production of <t>lentiviral</t> VLPs. (a) Schematic diagrams of the three <t>VLP</t> expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Lentiviral Vlp Stock, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lentiviral vlp stock/product/Worthington Biochemical
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    lentiviral vlp stock - by Bioz Stars, 2021-01
    85/100 stars
      Buy from Supplier

    88
    Worthington Biochemical cap24
    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various <t>CAp24</t> inoculation amounts, as indicated. Transduced
    Cap24, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cap24/product/Worthington Biochemical
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cap24 - by Bioz Stars, 2021-01
    88/100 stars
      Buy from Supplier

    Image Search Results


    Nullbasic inhibits reverse transcription of lentiviral VLPs.  (a)  Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Purification, Activity Assay

    Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Plasmid Preparation

    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Purification, Activity Assay

    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Infection, Produced

    HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Infection

    HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Infection